Minimed Group, INC

MiniMed Group, Inc. reports the resignation of its Senior Vice President, General Counsel, and Corporate Secretary, Courtney Nelson Wills, effective September 25, 2026.

MiniMed Group, Inc. announced an expansion of its Board of Directors with two new appointments and set the date and record date for its 2026 Annual Meeting of Stockholders.

MiniMed announced record fiscal year 2026 net sales exceeding $3 billion, with Q4 sales up 15.6% year-over-year, driven by international markets and new product clearances.

MiniMed Group, Inc. reports the resignation of director Brett Wall and the appointment of Scott Cundy to the Board of Directors.

MiniMed Group, Inc. disclosed that its parent company, Medtronic plc, experienced a cybersecurity incident involving unauthorized access to IT systems, with no expected material impact on MiniMed's business or financial results.

MiniMed Group, Inc. approved new severance and change of control plans for its executives, enhancing benefits for eligible terminations.

MiniMed Group reports Q3 2026 net sales of $790 million, reflecting a 15% increase, alongside a net loss of $111 million driven by restructuring and litigation charges.

MiniMed Group, Inc. announced its fiscal year 2026 results, showcasing a 14% increase in net sales to $3.1 billion, primarily fueled by robust international growth in its CGM segment.

Courtney Nelson Wills, SVP, Gen. Counsel, Corp. Sec. of MiniMed Group, Inc., reported a transaction in 1,762 shares of common stock on July 31, 2026.

Ali Dianaty, EVP Ch. Prod. & Tech Officer of MiniMed Group, Inc., reported a transaction in 8,012 shares of common stock on July 31, 2026.

Que Dallara, Chief Executive Officer and a Director of MiniMed Group, Inc., reported a transaction in 31,350 shares of common stock on July 31, 2026.

Chad Spooner, EVP, Chief Financial Officer of MiniMed Group, Inc., reported a transaction in 23,301 shares of common stock on July 28, 2026.

Gillian Chandrasena, SVP, Chief HR Officer of MiniMed Group, Inc., reported a transaction in 2,099 shares of common stock on July 28, 2026.

Courtney Nelson Wills of MiniMed Group, Inc. was granted restricted stock units and acquired additional shares, increasing beneficial ownership.

MiniMed Group, a global leader in diabetes technology, filed an S-1/A for its initial public offering of 28 million shares, showcasing robust revenue growth and product innovation despite reporting significant net losses and operational challenges.

MiniMed Group, Inc., a global medical technology company specializing in diabetes management, filed an amended S-1 registration statement detailing its initial public offering of 28 million shares and its spin-off from Medtronic, aiming to accelerate growth as an independent entity.

Medtronic plc has filed a Schedule 13G reporting beneficial ownership of 90% of the outstanding common stock of MiniMed Group, Inc.